HYHan Yao

Han Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Han Yao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Donglai Wang

    State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    6 shared publications
  • Wei Gu

    Institute for Cancer Genetics, and Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, USA

    5 shared publications
  • Xiaojun Yan

    State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Yajing Liu

    State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Zhen Wu

    State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Dongkui Xu

    Department of VIP , National Cancer Center & National Clinical Research Center for Cancer & Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China

    4 shared publications

Latest Publications

  • Open Access

    Supplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy

    by Xiaojun Yan, Wenbin Xu, Han Yao, Zhen Wu, Jingyuan Ning, Shidong Zhao, Yajing Liu, Meng Zhang, Dongkui Xu, Zhanlong Shen, et al.

    Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.

  • Open Access

    Data from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy

    by Xiaojun Yan, Wenbin Xu, Han Yao, Zhen Wu, Jingyuan Ning, Shidong Zhao, Yajing Liu, Meng Zhang, Dongkui Xu, Zhanlong Shen, et al.

    Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.

  • Open Access

    Source Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy

    by Xiaojun Yan, Wenbin Xu, Han Yao, Zhen Wu, Jingyuan Ning, Shidong Zhao, Yajing Liu, Meng Zhang, Dongkui Xu, Zhanlong Shen, et al.

    This file contains the raw data of this study.

  • Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy

    by Xiaojun Yan, Wenbin Xu, Han Yao, Zhen Wu, Jingyuan Ning, Shidong Zhao, Yajing Liu, Meng Zhang, Dongkui Xu, Zhanlong Shen, et al.

    Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses. Significance: This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.


  • Open Access

    Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1

    by Jia Wen, Han Yao, Zhijie Cao, Donglai Wang

    Since the recent discovery of cancer cell-intrinsic programmed cell death protein-1 (PD-1), the mechanisms that manipulate PD-1 functions in tumor development beyond its immune checkpoint roles have become attractive research topics in oncology. Our previous study validated that PD-1 exists in lung cancer cells and is directly transactivated by p53 in a DNA-binding domain (DBD) acetylation-dependent manner. Here, we report that the carboxyl-terminal domain (CTD) of p53 likewise participates in PD-1 transcriptional regulation in cancer cells un-der different regulatory mechanisms. By mutating the lysine residues within the CTD to mimic either acetylation-deficient or fully acetylated status, we proved that acetylated CTD dramatically impeded p53-mediated trans-activation of PD-1. Furthermore, we identified bromodomain-containing protein 4 (BRD4) as a transcriptional coactivator of p53 that facilitates p53-mediated PD-1 transcription. Mechanistically, BRD4 specifically bound to the unacetylated CTD of p53, while CTD acetylation almost completely destroyed the BRD4-p53 interac-tion and thus led to compromised PD-1 expression. Collectively, this study unveils an alternative mechanism of p53 acetylation-directed PD-1 transcriptional regulation, which would broaden our current understanding of the molecular regulatory network of cancer cell-intrinsic PD-1.


  • Open Access

    An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation

    by Zhijie Cao, Ning Kon, Yajing Liu, Wenbin Xu, Jia Wen, Han Yao, Mi Zhang, Zhen Wu, Xiaojun Yan, Wei-Guo Zhu, et al.

    Activation of PD-1 by p53 is critical for its tumor suppression in an immunity-independent manner.